January 2026 in “Journal of Dermatological Treatment” This source discusses a Phase 2 trial by Hu et al. that evaluated the efficacy of topical GT20029 compared to a placebo, though the abstract does not provide specific results.
December 2025 in “Journal of Dermatological Treatment” This randomized trial found that topical GT20029 significantly increased hair counts and width in Chinese men with androgenetic alopecia over 12 weeks, showing better results than placebo, with the 0.5% once daily and 1.0% twice weekly doses particularly effective.
In this multicenter Phase II trial, researchers found that topical GT20029 significantly increased hair regrowth in Chinese adult males with androgenetic alopecia compared to placebo, demonstrating good tolerability and suggesting the need for further studies to confirm its therapeutic potential.
This Phase II trial found that topical GT20029 significantly increased hair count and width at 12 weeks in Chinese men with androgenetic alopecia compared to placebo, with good tolerability and similar adverse event incidence across groups.
9 citations
,
October 2025 in “MedComm” This review discusses the development and clinical progression of PROTAC technology for targeted protein degradation, highlighting its potential to address previously "undruggable" targets but reports no new clinical results.
3 citations
,
October 2025 in “Cancer” This review highlights the potential of PROTACs to transform cancer treatment by selectively degrading oncogenic proteins, overcoming drug resistance, and reducing toxicity; it also discusses challenges in optimizing these therapies for personalized applications.
January 2026 in “OSF Preprints (OSF Preprints)” In this study, researchers presented a novel therapeutic approach for androgenetic alopecia combining AR-PROTAC degradation with regenerative strategies and evaluated the potential of GT20029 as a topical treatment, proposing a three-phase protocol and future research hypotheses.
November 2025 in “Journal of Medicinal Chemistry” This review outlines advances in topical PROTACs for localized protein degradation, focusing on AH-001 and GT20029 for skin conditions, but presents no new clinical trial results.
This study performed a bibliometric analysis of the 100 most cited articles on androgenetic alopecia from 1975 to 2024, revealing that U.S. authors contributed most and highlighting a trend toward research focused on treatment options, especially between 2020 and 2024.
July 2024 in “Forum Dermatologicum” This review evaluates various topical treatments for androgenetic alopecia but does not provide new clinical findings, emphasizing the need for selecting therapies with limited systemic side effects.
June 2026 in “Expert Opinion on Pharmacotherapy” This article reviews emerging therapies for androgenetic alopecia, highlighting advances like androgen-receptor antagonists and improved minoxidil delivery that aim to enhance treatment efficacy and safety.
March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)” This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
January 2025 in “Annals of Dermatology” This review discusses current and emerging treatments for androgenetic alopecia, covering mechanisms, efficacy, and safety of both androgen-targeted and non-androgen-targeted approaches, but reports no new clinical results.
February 2026 in “Journal of Dermatological Treatment” This research describes CG2001's promising safety profile and reduced systemic exposure as an alternative to finasteride, supporting its further development for androgenic alopecia treatment in future trials.
This article reviews approved treatments for androgenetic alopecia and reports no new research findings, highlighting the need for further studies.
In this phase I study, CG2001, a topical foam combining minoxidil and finasteride, was found to be safe and well-tolerated in Chinese males with androgenetic alopecia, showing significantly reduced systemic finasteride exposure compared to oral administration, potentially reducing related side effects.
This study found that the novel alcohol-free topical foam CG2001, combining minoxidil and finasteride, was safe and well-tolerated in Chinese males with androgenetic alopecia, with significantly lower systemic exposure to finasteride compared to oral administration, potentially reducing sexual side effects.
40 citations
,
January 2017 in “Intestinal Research” This study found that among Japanese IBD patients, the NUDT15 p.Arg139Cys variant was significantly associated with thiopurine-induced leukopenia and severe hair loss, suggesting its genotyping is important for predicting these adverse events.
7 citations
,
March 2004 in “Journal of the American Academy of Dermatology” Tiger tail banding and hair abnormalities are reliable indicators for diagnosing trichothiodystrophy.
August 2025 in “Skin Research and Technology” This study discusses the potential of miR-200c-3p as a genetic marker and therapeutic tool for alopecia areata, but it highlights the need for additional methodological details and addresses discrepancies with previous findings on miRNA expression in hair-related processes.
3 citations
,
January 2021 in “Molecular genetics & genomic medicine” In this study, novel mutations in the BTD gene were identified in a patient with profound biotinidase deficiency, highlighting the importance of biotinidase activity measurement and mutation analysis for early diagnosis.
January 2026 in “American Journal of Medical Genetics Part A” The researchers reported two brothers with a new variant of X-linked trichothiodystrophy associated with an RNF113A gene mutation, highlighting features such as intellectual disability and growth failure, but without previously reported endocrinological or genital abnormalities, underlining the importance of genetic counseling for such variants.
3 citations
,
February 2019 in “Molecular genetics and metabolism” This study found that coadministration of tadalafil and finasteride improved lower urinary tract symptoms and erectile function in men with benign prostatic hyperplasia better than finasteride alone over 26 weeks.
19 citations
,
November 1971 in “Clinica Chimica Acta” In this study, the researchers found that the absence of the NFI-C transcription factor delayed the hair growth cycle in mice by affecting key gene expressions and signaling pathways.
December 2022 in “Frontiers in Pharmacology” This study reported that Tianma Gouteng decoction improved hair follicle regeneration in mice and identified its potential mechanism, primarily involving the Wnt/β-catenin signaling pathway, through a combination of network pharmacology, molecular docking, and experimental validation.
October 2025 in “Animals” This study explored the genetic regulation of goose feather follicle development, identifying miR-200a as a key regulator that inhibits GEDF proliferation through the Wnt pathway, potentially impacting goose down quality and supporting selective breeding strategies.
November 2006 in “評価・診断に関するシンポジウム講演論文集” This study found that KSR1 is essential for v-Ha-ras-mediated skin tumor formation in mice but not for MT-driven mammary tumor genesis, suggesting its potential as a therapeutic target in Ras/MAPK signaling.
7 citations
,
March 2024 in “Skin Research and Technology” This study identified miR-200c-3p as influencing key genes in the EGFR resistance pathway, suggesting its potential theranostic role in addressing issues related to this pathway.
This paper introduces the clinical efficacy of a modified Renshen Yangrong Tang formula for treating viral hepatitis, insomnia, hair loss, and prolonged menstrual periods, emphasizing its application for qi and blood deficiency.
4 citations
,
January 2004 This study found that while some extracts from DanGuiBoHyulTangGami-Bang showed potential in inhibiting 5-reductase type Ⅱ and had antioxidant activity, they were not effective in extending the hair growth period.